Kisspeptin-10 vs MOTS-c

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

Kisspeptin-10MOTS-c
CategoryPeptidesPeptides
Standard DoseResearch indicates 1-10 mcg/kg via subcutaneous injection or IV bolus for acute HPG axis stimulation.Research indicates 5-10 mg administered 3-5 times per week via subcutaneous injection.
TimingMorning dosing preferred for testosterone optimization. Can be used acutely before sexual activity.Morning administration preferred. Can be dosed pre-workout for enhanced exercise performance.
Cycle DurationShort-term use only. Continuous kisspeptin administration may cause tachyphylaxis (desensitization) of the HPG axis.8-16 week cycles.
Evidence Levelmoderate_humanEmerging (strong preclinical)
A

Kisspeptin-10

Peptides

Mechanism

Kisspeptin-10 is the 10-amino acid C-terminal fragment of the kisspeptin family that signals directly to GnRH neurons through the kisspeptin receptor (KISS1R/GPR54), triggering GnRH release into the portal circulation. This stimulates LH and FSH secretion from anterior pituitary gonadotrophs. In men, intravenous kisspeptin-10 produces rapid dose-dependent LH rises (4.1 to 12.4 IU/L at 1 mcg/kg within 30 minutes), increases LH pulse frequency and amplitude, and subsequently elevates testosterone through the HPG axis.

Standard Dosing

Research indicates 1-10 mcg/kg via subcutaneous injection or IV bolus for acute HPG axis stimulation.

Timing

Morning dosing preferred for testosterone optimization. Can be used acutely before sexual activity.

Cycle Duration

Short-term use only. Continuous kisspeptin administration may cause tachyphylaxis (desensitization) of the HPG axis.

Side Effects

  • Facial flushing
  • Mild nausea
  • Elevated LH/testosterone (desired effect)
  • Potential for HPG axis desensitization with prolonged use

Contraindications

  • Hormone-sensitive cancers (prostate, breast)
  • Pregnancy and breastfeeding
  • Children/adolescents (premature puberty risk)

Best Stacking Partners

PT-141HCG
B

MOTS-c

Peptides

Mechanism

MOTS-c is a 16-amino acid mitochondrial-derived peptide encoded by the 12S rRNA gene of the mitochondrial genome. It primarily acts through the folate-AICAR-AMPK pathway: by regulating the folate cycle and de novo purine biosynthesis, it increases AICAR accumulation, which phosphorylates and activates AMPK. This enhances glucose uptake in skeletal muscle, improves insulin sensitivity, and mimics exercise-mediated physiological responses. Skeletal muscle MOTS-c levels increase 11.9-fold in response to acute exercise in young men.

Standard Dosing

Research indicates 5-10 mg administered 3-5 times per week via subcutaneous injection.

Timing

Morning administration preferred. Can be dosed pre-workout for enhanced exercise performance.

Cycle Duration

8-16 week cycles.

Side Effects

  • Injection site reactions
  • Mild fatigue post-injection
  • Transient flushing
  • Muscle soreness (exercise-mimetic effect)

Contraindications

  • Pregnancy and breastfeeding
  • Type 1 diabetes (insulin sensitivity changes require monitoring)
  • Not FDA-approved
  • Limited human safety data
  • Active cancer (metabolic pathway activation)

Best Stacking Partners

5-Amino-1MQAOD-9604Semaglutide

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →